

Vor ref 22259 XX 1

PATENTFAMILIE DE 30 22 337

20. november 1998

1

File 351:DERWENT WPI 1963-1998/UD=9846;UP=9843;UM=9841
(c)1998 Derwent Info Ltd

1/7/1

DIALOG(R)File 351:DERWENT WPI

(c)1998 Derwent Info Ltd. All rts. reserv.

003444375

WPI Acc No: 82-01972E/*198202*

Compsns. for contraception or treatment of gynaecological disorders -
contg. 6 beta, 7 beta; 15 delta, 16

beta-dimethylene-3-oxo-4-androstene-17(beta-1')-spiro-5'-perhy-
dro-furan-2'-one

Patent Assignee: SCHERING AG (SCHD)

Inventor: BEIER S; ELGER W; MANNESMANN G; SCHILLINGE E

Number of Countries: 001 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
DE 3022337	A	19820107	DE 3051166	A	19800611		198202 B
DE 3051166	A	19890323	DE 3022337	A	19800611		198913
DE 3022337	C	19891019				198942	
DE 3051166	C	19901018				199042	

Priority Applications (No Type Date): DE 3022337 A 19800611; DE 3051166 A 19800611

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
DE 3022337	A		9			

Abstract (Basic): DE 3022337 A

New preps. for contraception and for the treatment of
gynaecological disorders are based on 6 beta, 7 beta; 15 beta, 16
beta-dimethylene -3-oxo-4-androstene/17 (beta-1')-spiro-5'
/-perhydrofuran-2'-one (I).

(I) (a known aldosterone-antagonist diuretic) has been found to
display marked gestagenic activity, as shown by its positive effects in
a modified Clauberg test in rabbits at dosages of 0.1-1.0 mg s.c. It
may be used alone or in combination with an oestrogen as a
contraceptive agent, esp. in women suffering from high blood pressure
or in whom oral contraceptives cause hypertension. (I) may also be used
for the treatment of premenstrual disorders. It is similar to
progesterone in its combination of gestagenic and
anti-mineralocorticoid properties, with the advantage of oral activity.

Derwent Class: B01

International Patent Class (Additional): A61K-031/56